PAVBLU
Live / Registered — Registered (as of 18 Mar 2025)
What this means for you
Registered since 18 Mar 2025. The owner can stop confusingly similar uses in the classes it covers; it stays on the register as long as the owner keeps up the maintenance filings (next due by 18 Mar 2031: the §8 declaration of use).
Record
- Serial number
- 97353493
- Registration number
- 7732496
- Mark type
- Word mark
- Filed
- 08 Apr 2022
- Published for opposition
- 04 Apr 2023
- Registered
- 18 Mar 2025
- Next maintenance filing
- §8 declaration of use, due by 18 Mar 2031 (grace period to 18 Sept 2031)
- Attorney of record
- ELSA D. LEMOINE
Goods and services
- Class 005 — Pharmaceuticals: pharmaceutical preparations and substances for the treatment of ophthalmic diseases and disorders
Owner
- Amgen Inc., Thousand Oaks, CA, US
- Amgen Inc., Thousand Oaks, CA, US
- Amgen Inc., Thousand Oaks, CA, US
Board proceedings on this mark
- Opposition No. 91287397 — Novartis AG v. Amgen Inc., filed 28 Sept 2023 (Terminated)
- Extension of Time to Oppose No. 97353493 — Novartis AG v. Amgen Inc., filed 27 Apr 2023 (Terminated)
Prosecution history
- 18 Mar 2025 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 18 Mar 2025 — REGISTERED-PRINCIPAL REGISTER
- 21 Feb 2025 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 21 Feb 2025 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 03 Feb 2025 — ASSIGNED TO EXAMINER
- 21 Jan 2025 — STATEMENT OF USE PROCESSING COMPLETE
- 05 Nov 2024 — USE AMENDMENT FILED
- 21 Jan 2025 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 05 Nov 2024 — TEAS STATEMENT OF USE RECEIVED
- 25 Oct 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 25 Oct 2024 — SOU EXTENSION 2 GRANTED
- 25 Oct 2024 — SOU EXTENSION 2 FILED
- 25 Oct 2024 — SOU TEAS EXTENSION RECEIVED
- 16 Apr 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 15 Apr 2024 — SOU EXTENSION 1 GRANTED